Tesamorelin

Tesamorelin is a stabilized analog of human growth hormone-releasing hormone (1-44), approved in some jurisdictions for HIV-associated lipodystrophy. It is among the few peptides in this library with Phase III efficacy and safety data.

Binding to the pituitary GHRH receptor stimulates endogenous, pulsatile release of growth hormone, preserving physiological feedback via somatostatin and IGF-1. Increased GH raises hepatic IGF-1 production and promotes lipolysis, with a preferential effect on visceral adipose tissue.

Store the sealed lyophilized vial at 2-8 °C, protected from light; brief exposure to room temperature during shipping is generally tolerated. Refrigerate after reconstitution at 2-8 °C and use within the period supported by stability data for the substance (typically 2-4 weeks). Avoid repeated freeze-thaw cycles: each cycle increases the risk of aggregation and hydrolysis of the peptide bond. Do not shake the vial; swirl gently and direct the liquid stream against the glass wall rather than at the powder cake.

• Sealed lyophilized vial, stored as supplied
• Bacteriostatic water (0.9% benzyl alcohol) for reconstitution
• Insulin syringes (29-31G, 0.5 mL / 100 units)
• Reconstitution syringe (1-3 mL, 21-23G needle)
• 70% isopropyl alcohol swabs
• Sharps container for used needles
• Labels and a logbook for batch, date and volume

Phase III trials reported an approximately 15-18% reduction in visceral adipose tissue over 26 weeks, with improvements in triglycerides. Reported adverse effects include arthralgia, peripheral edema, injection-site erythema and glucose intolerance. IGF-1 monitoring is standard in the clinical literature.

Wash your hands, then disinfect the vial septum and the injection site with 70% isopropyl alcohol and allow both to air dry. Draw up the intended volume, remove air bubbles and pinch a subcutaneous skin fold. Insert at a 45-90° angle depending on fat thickness, aspiration is not required for subcutaneous administration, and inject slowly. Withdraw the needle, apply light pressure and discard the needle in a sharps container. Rotate injection sites systematically (abdominal quadrants, flanks, thighs) to prevent lipohypertrophy and local irritation.

Peptide research protocols are studied against a background of adequate protein intake (approximately 1.6-2.2 g/kg/day in the training literature), consistent sleep of 7-9 hours, and controlled training load. Sleep deprivation and chronic psychological stress both dampen growth hormone pulsatility and disrupt tissue remodeling, complicating the interpretation of any observed effect. Alcohol, smoking and large caloric deficits are likewise documented modifiers of recovery outcomes.

1. Falutz J. et al. Metabolic effects of tesamorelin in HIV-associated abdominal fat accumulation. N Engl J Med, 2007.
2. Stanley T.L. et al. Effects of tesamorelin on visceral fat and liver fat. JAMA, 2014.
3. Clemmons D.R. et al. Safety and metabolic effects of tesamorelin. Endocr Pract, 2017.